Various methods can be used to measure pharmacokinetics of platinum agents. Atomic absorption spectrometry (AAS) measures total platinum regardless of the chemical structure of the metabolite. We are presenting an inexpensive method to determine the total cytotoxicity of Pt-drug in patient's serum and urine samples. 50 μl of urine and serum samples with ex vivo added cisplatinum were added to cell cultures of U251 human glioma cells. The cytotoxicity of the samples was compared to a standard curve created with cisplatinum in cell culture medium. The lower detection limit was 0.1 μM for cisplatinum in urine. Serum required heat inactivation first, and had a detection limit of 1 μM. Finally, urine of a patient receiving cisplatinum for treatment was analyzed with the bioassay and compared to measurements with AAS. The cytotoxic activity of cisplatin in this patient's urine was 50% as compared to non-metabolized cisplatin, suggesting that the AAS measured Platinum included inactivated drug metabolites, which shows the potential benefit of complementing AAS measurements with the MTT-bioassay.
|Original language||English (US)|
|Number of pages||4|
|Journal||Turkish Journal of Cancer|
|State||Published - Apr 1 2004|
- MTT assay
ASJC Scopus subject areas